Silexion Therapeutics Raises $1.0M via Warrant Inducement, Issues New Warrants
SLXN sits 28% above its 52-week low of $0.231 on elevated volume (30× avg).
Summary
Silexion Therapeutics has secured approximately $1.0 million in gross proceeds through an inducement offer for existing warrant holders to exercise their warrants. In exchange, the company will issue 3,990,184 new Series C and D warrants at $0.50 per share, and has engaged H.C. Wainwright as its exclusive placement agent. This capital raise is highly significant for Silexion, which previously disclosed a "going concern" warning in its March 2026 10-K, indicating limited cash runway. While the $1.0 million provides critical short-term liquidity for the micro-cap company, the issuance of new warrants represents substantial potential dilution for existing shareholders. Investors will be watching how this capital extends the company's operational runway and its impact on the stock, especially following recent positive clinical updates for its lead drug candidate, SIL204.
At the time of this announcement, SLXN was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.23 to $22.36. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.